What is the Return on Assets (ROA) of Immunovant this year?
The Return on Assets (ROA) of Immunovant is -0.39 undefined this year.
Immunovant ROA 2024
Immunovant ROA
-0.39
Ticker
IMVT
ISIN
US45258J1025
In 2024, Immunovant's return on assets (ROA) was -0.39, a 28.03% increase from the -0.3 ROA in the previous year.
Immunovant Aktienanalyse
What does Immunovant do?
Immunovant ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Immunovant's Return on Assets (ROA)
Immunovant's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Immunovant's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Immunovant's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Immunovant’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Immunovant Stock
What was the ROA of Immunovant compared to the previous year?
The ROA of Immunovant has increased by 28.03% compared to the previous year.
What consequences do high ROA have for investors of Immunovant?
A high ROA is advantageous for investors of Immunovant, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Immunovant?
A low ROA can be unfavorable for investors of Immunovant as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Immunovant affect the company?
An increase in ROA of Immunovant can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Immunovant impact the company?
A reduction in the ROA of Immunovant can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Immunovant?
Some factors that can influence the ROA of Immunovant include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Immunovant important for investors?
The ROA of Immunovant is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Immunovant take to improve ROA?
To improve ROA, Immunovant can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Immunovant pay?
Over the past 12 months, Immunovant paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovant is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunovant?
The current dividend yield of Immunovant is .
When does Immunovant pay dividends?
Immunovant pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunovant?
Immunovant paid dividends every year for the past 0 years.
What is the dividend of Immunovant?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunovant located?
Immunovant is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunovant kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunovant from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.
When did Immunovant pay the last dividend?
The last dividend was paid out on 7/1/2024.
What was the dividend of Immunovant in the year 2023?
In the year 2023, Immunovant distributed 0 USD as dividends.
In which currency does Immunovant pay out the dividend?
The dividends of Immunovant are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunovant
Our stock analysis for Immunovant Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovant Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.